Monitor stock price relative to the $1.46 warrant exercise price; if DRMA trades above $1.46, warrant cash exercise could provide working capital but also accelerate dilution. The S-3 is a resale registration, not a primary offering — no immediate capital raise event.
Price Chart
Executive Summary
Dermata Therapeutics filed an S-3 registration statement to register up to 6,919,560 shares of common stock for resale by selling stockholders, including shares and warrants issued in an August 2026 private placement. The company will not receive any proceeds from the resale, but may receive cash exercise proceeds from outstanding warrants. The filing is a routine contractual obligation under a registration rights agreement and does not represent a new capital raise, though the potential for warrant exercise creates modest future dilution overhang.
Key Facts
- Registers up to 6,919,560 shares for resale by selling stockholders, including 933,064 common shares, 1,361,470 pre-funded warrant shares, 2,294,534 Series E warrant shares, 2,294,534 Series F warrant shares, and 35,958 bank warrant shares.
- Shares and warrants were issued in a private placement that closed on August 18, 2026, with aggregate gross proceeds of approximately $2.4 million from insider purchases.
- Company will not receive proceeds from resales; only from any cash exercise of warrants (Series E at $1.46, Series F at $1.46, Bank at $1.825).
- As of October 9, 2026, there were 4,955,207 shares outstanding; the registered shares represent ~140% of current float if all warrants are exercised.
- CEO Gerald Proehl and CFO Kyri Van Hoose participated in the private placement, purchasing $2.4 million aggregate of shares and warrants.
- Last reported stock price on October 6, 2026 was $1.13, below the $1.46 warrant exercise price, making near-term cash exercise unlikely.
Financial Impact
Maximum potential dilution of up to 6,919,560 shares (140% of current 4,955,207 shares outstanding) if all warrants are exercised; no new capital raised from resales; potential cash proceeds from warrant exercise at $1.46-$1.825 per share if stock price recovers above those levels.
Risk Factors
- Massive potential dilution (~140% of current float) if all warrants are exercised and shares are sold into the market.
- Warrant exercise price of $1.46 is above the current $1.13 stock price, making cash exercise unlikely in the near term.
- Company has a going concern uncertainty noted in the audited financial statements, indicating ongoing capital needs.
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001493152-26-046518 |
| Exhibit: ex107.htm | 0001493152-26-046518 |
| Exhibit: ex5-1.htm | 0001493152-26-046518 |
| Exhibit: ex23-1.htm | 0001493152-26-046518 |
| Document: 0001493152-26-046518-index-headers.html | 0001493152-26-046518 |
| Document: 0001493152-26-046518-index.html | 0001493152-26-046518 |
| Document: 0001493152-26-046518.txt | 0001493152-26-046518 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | EFFECT | $0.8000 $0.8640 | ▼ −8.00% | ▼ −9.18% | $0.7550 (+5.63%) |
Oct 9, 2026 18d ago | S-3 | $0.8896 $0.8599 | ▼ −3.34% | ▼ −3.33% | $0.7550 (−15.13%) |
Aug 17, 2026 10w ago | 8-K | $1.46 $1.43 | ▲ +2.05% | ▲ +1.38% | $0.7550 (+48.29%) |
Aug 5, 2026 11w ago | 8-K | $1.17 $1.11 | ▼ −5.13% | ▼ −4.97% | $0.7550 (−35.47%) |
Feb 25, 2026 34w ago | 8-K | $1.25 $1.20 | ▼ −4.00% | ▼ −3.52% | $0.7550 (−39.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers